Akouos to Present at Upcoming October Virtual Investor Conferences

Rhea-AI Summary

Akouos, a precision genetic medicine company, announced that its CEO, Manny Simons, will present at two virtual investor conferences in October 2020. The first is the Jefferies Gene Therapy/Editing Summit on October 1, and the second is the Chardan Annual Genetic Medicines Conference on October 5. Both events will feature fireside chats. Live webcasts will be accessible via the company's website, with replays available for 14 days post-conference. Akouos focuses on gene therapies aimed at restoring hearing for individuals with disabling hearing loss.

BOSTON, Sept. 24, 2020 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that Manny Simons, Ph.D., M.B.A., CEO, President and co-founder, will present at two upcoming virtual investor conferences in October:

• Jefferies Gene Therapy/Editing Summit. Fireside chat on Thursday, October 1 at 8:00 a.m. ET
• Chardan Annual Genetic Medicines Conference. Fireside chat on Monday, October 5 at 8:30 a.m. ET

A live webcast of each fireside chat will be accessible through the investors section of the company’s website at www.akouos.com. To access the webcasts, please go on to the Akouos website approximately 15 minutes prior to the start time to ensure adequate time for any software downloads that may be required. Replays of each webcast will be available on Akouos’s website for 14 days following the conferences.

About Akouos
Akouos is a precision genetic medicine company dedicated to developing gene therapies with the potential to restore, improve, and preserve high-acuity physiologic hearing for individuals living with disabling hearing loss worldwide. Leveraging its precision genetic medicine platform that incorporates a proprietary adeno-associated viral (AAV) vector library and a novel delivery approach, Akouos is focused on developing precision therapies for forms of sensorineural hearing loss. Headquartered in Boston, Akouos was founded in 2016 by leaders in the fields of neurotology, genetics, inner ear drug delivery, and AAV gene therapy.

Contacts
Media:
Katie Engleman, 1AB
katie@1abmedia.com

Investors:
Courtney Turiano, Stern Investor Relations
Courtney.Turiano@sternir.com

FAQ

What are the dates for Akouos' upcoming investor conferences?

Akouos will present at two investor conferences: the Jefferies Gene Therapy/Editing Summit on October 1, 2020, and the Chardan Annual Genetic Medicines Conference on October 5, 2020.

Who will represent Akouos at the investor conferences?

Manny Simons, Ph.D., M.B.A., the CEO and co-founder of Akouos, will represent the company at the upcoming investor conferences.

Where can I access the live webcasts of Akouos' presentations?

The live webcasts of Akouos' presentations will be accessible through the investors section of their website at www.akouos.com, available approximately 15 minutes prior to the events.

How long will the webcasts be available after the conferences?

Replays of the webcasts will be available on Akouos' website for 14 days following each conference.

What is the primary focus of Akouos as a company?

Akouos specializes in developing precision gene therapies aimed at restoring, improving, and preserving hearing for individuals living with disabling hearing loss.